At the news
? BULLISHIMPACT 5/10 8-K filed Sep 15, 2026 at 21:17 ET
NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from a Major Amendment to a Minor Amendment, pulling the GDUFA goal date forward to November 10, 2026. This regulatory de-escalation signals a lower review burden and accelerates the timeline toward potential approval of a drug-shortage product, a modest but positive catalyst for a clinical-stage biopharma with a $147M market cap.
- FDA reclassified NRx's ANDA amendment from Major to Minor Amendment.
- GDUFA goal date revised to November 10, 2026.
- FDA cited the reclassified amendment will not require a substantial expenditure of resources.
- Product is preservative-free ketamine (NRX-100), designated a drug shortage product.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access